AN OPEN-LABEL, NONCOMPARATIVE STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF AZITHROMYCIN IN THE TREATMENT OF PATIENTS WITH ACUTE SINUSITIS

被引：11

作者：

AMIN, NM

BREADON, G

机构：

[1] Department of Family Practice, Kern Medical Center, Bakersfield, CA

[2] Department of Otolaryngology, Head and Neck Surgery, The Monroe Clinic, Monroe, WI

来源：

CLINICAL THERAPEUTICS | 1995年 / 17卷 / 04期

关键词：

D O I：

10.1016/0149-2918(95)80046-8

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The efficacy, safety, and tolerability of a 5-day, once-daily course of azithromycin were assessed in patients with acute sinusitis. Patients received two 250-mg capsules of azithromycin on day 1 and one 250-mg capsule on days 2 through 5. Of 102 clinically assessable patients, 27 (26.5%) were cured and 69 (67.6%) were improved on days 5 to 7. At days 12 to 16, 88 (86.3%) had a favorable clinical response. A total of 64 patients experienced adverse events; in all but two patients, adverse events were of mild or moderate severity. Thus azithromycin given once daily for 5 days was an effective treatment for patients with acute sinusitis.

引用

页码：701 / 707

页数：7

共 17 条

[1] Fiese, Steffen, Comparison of acid stability of azithromycin and erythromycin A, J Antimicrob Chemother, 25, pp. 39-47, (1990)
[2] Bright, Nagel, Bordner, Et al., Synthesis in vitro and in vivo activity of novel 9-deoxo-9a-aza-9a-homerythromycin A derivatives A new class of macrolide antibiotics the azalides, The Journal of Antibiotics, 41, pp. 1029-1047, (1988)
[3] Retsema, Girard, Schelkly, Et al., Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms, Antimicrob Agents Chemother, 31, pp. 1939-1947, (1987)
[4] Goldstein, Emirian, Coutrot, Acar, Bacteriostatic and bactericidal activity of azithromycin against Haemophilus influenzae, J Antimicrob Chemother, 25, pp. 25-28, (1990)
[5] Hardy, Hensey, Beyer, Et al., Comparative in vitro activities of 14- 15- and 16-membered macrolides, Antimicrobial Agents and Chemotherapy, 32, pp. 1710-1719, (1988)
[6] Foulds, Shepard, Johnson, The pharmacokinetics of azithromycin in human serum and tissues, J Antimicrob Chemother, 25, pp. 73-82, (1990)
[7] Karma, Pukander, Penttil, Azithromycin concentrations in sinus fluid and mucosa after oral administration, Eur J Clin Microbiol Infect Dis, 10, pp. 856-859, (1991)
[8] Coates, Daniel, Houston, Et al., An open study to compare the pharmacokinetics, safety and tolerability of a multiple-dose regimen of azithromycin in young and elderly volunteers, Eur J Clin Microbiol Infect Dis, 10, pp. 850-852, (1991)
[9] Gladue, Bright, Isaacson, Et al., In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: Possible mechanism of delivery and release at sites of infection, Antimicrob Agents Chemother, 33, pp. 277-282, (1989)
[10] Panteix, Guillaumond, Harf, Et al., In-vitro concentration of azithromycin in human phagocytic cells, J Antimicrob Chemother, 31, pp. 1-4, (1993)

← 1 2 →